FDA Removes GHK-Cu from Category 2: What Peptide Users Need to Know
On April 15, 2026, the FDA announced it will remove injectable GHK-Cu from Category 2 — the list that blocked compounding pharmacies from producing it. This is a major regulatory shift for one of the most studied copper peptides in longevity research.
On April 15, 2026, the FDA announced it will remove injectable GHK-Cu from Category 2 — the list that blocked compounding pharmacies from producing it. This is a major regulatory shift for one of the most studied copper peptides in longevity research.
Peptide South Africa Research Research TeamEditorial
#GHK-Cu#Compounding#FDA#longevity#Regulatory#anti-aging#Copper PeptideShare this articleTwitterLinkedInTrack Your Peptide Protocols
Use Peptide South Africa Research to log injections, calculate doses, access our peptide library, and optimize your protocols.
Download Peptide South Africa ResearchExplore More Peptide ResourcesFree peptide calculators·Peptide research hub·Peptide glossary·Semaglutide guide·BPC-157 guide·Best peptide calculator